Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.58 |
| ▸ | TRHR | P34981 | 1/20 | 0.51 |
| ▸ | NLN | Q9BYT8 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 2/20 | 0.46 |
| ▸ | REN | P00797 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477930 | 0.87 | DPP4 (0.71) | DPP4DPP7TRHRNLNCYP3A4 | |
| SCHEMBL26625862 | 0.87 | DPP4 (0.71) | DPP4DPP7TRHRNLNCYP3A4 | |
| SCHEMBL27210419 | 0.87 | DPP4 (0.71) | DPP4DPP7TRHRNLNCYP3A4 | |
| SCHEMBL30839651 | 0.81 | TRHR (0.53) | DPP4TRHRREN | |
| SCHEMBL31649037 | 0.80 | DPP4 (0.71) | DPP4DPP7TRHRNLNCYP3A4 | |
| SCHEMBL22300350 | 0.80 | DPP4 (0.56) | DPP4DPP7TRHRNLNREN | |
| SCHEMBL27484466 | 0.79 | DPP4 (0.69) | DPP4DPP7TRHRNLNCYP3A4 | |
| SCHEMBL18621660 | 0.78 | FKBP1A (0.49) | DPP4DPP7PEPD | |
| SCHEMBL12658450 | 0.77 | DPP4 (0.62) | DPP4DPP7 | |
| SCHEMBL28202773 | 0.77 | DPP4 (0.62) | DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | disclosed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | DPP4 334/4885DPP7 294/4885TRHR 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.